Literature Review: Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion

Investigators explored ways to identify patients at increased risk of developing glaucoma or experiencing disease progression.

By Cissy Yang, MD; and Noga Harizman, MD
 

Rong AJ, Swaminathan SS, Vanner EA, Parrish RK 2nd1
Industry support: No

ABSTRACT SUMMARY

For this retrospective cohort study, investigators identified clinical risk factors for the development of neovascular glaucoma (NVG) after central retinal vein occlusion (CRVO). They reviewed the charts of 646 patients with CRVO who presented to the Bascom Palmer Eye Institute between 2013 and 2017. Ninety-eight of these patients met the study’s inclusion criteria: CRVO onset within 90 days of presentation, no anterior segment neovascularization on presentation, and no history of receiving an intravitreal anti-VEGF injection. Thirteen of the 98 patients (13%) developed NVG during an average follow-up duration of 17 months (range, 0.4–66.6 months). The mean time to NVG onset was 421 days after initial presentation and 212 days after the last intravitreal anti-VEGF injection.

Study in Brief

A retrospective cohort study found that a history of systemic hypertension, worse visual acuity, and the presence of a relative afferent pupillary defect at presentation were risk factors for developing neovascular glaucoma (NVG) after central retinal vein occlusion (CRVO) and that intravitreal anti-VEGF injections delayed but did not prevent the onset of NVG.

WHY IT MATTERS

NVG is a rare but potentially visually devastating complication of CRVO. To date, physicians’ ability to predict which patients will develop NVG after CRVO is limited. These investigators examined demographic data, systemic health data, and ophthalmologic examination findings to identify potential risks factors that may signal which patients are at increased risk of developing NVG. These patients may then be monitored more closely and for longer durations to allow prompt identification and treatment of neovascularization and thus prevent vision loss from glaucoma.

Patients who had a history of systemic hypertension (P = .026), a worse visual acuity on initial presentation (P = .034), or a relative afferent pupillary defect (RAPD, P = .002) were found to be at high risk of developing NVG. Age at presentation, sex, body mass index, systolic or diastolic blood pressure at the initial visit, a history of diabetes, degree of diabetic retinopathy, and IOP at presentation did not differ significantly between patients who developed NVG and those who did not. An anti-VEGF injection at the first visit did not reduce the risk of developing NVG, but it did delay the onset of NVG. Neither the presence of macular edema nor central retinal thickness at presentation was associated with an increased risk of NVG, which suggests that macular edema and NVG are independent sequelae of CRVO.

DISCUSSION

What was the relationship between intravitreal anti-VEGF injection and a patient’s risk of developing NVG?

Commonly referred to as 100-day glaucoma, the conversion to NVG after CRVO has been thought to occur within the first 3 months after CRVO onset. This impression is based on CRVO natural history studies conducted before the era of anti-VEGF therapy. Rong and colleagues found the time to NVG onset to be significantly longer than the commonly accepted 100 days, and they found no significant difference in the rate of NVG between patients who received anti-VEGF therapy and those who did not. The researchers concluded that anti-VEGF therapy may reset the clock, so to speak, and delay NVG onset but that therapy does not decrease a patient’s risk of developing NVG. Their findings suggest that eye care providers should observe CRVO patients receiving anti-VEGF injections closely for neovascularization beyond the traditional 90 days.

What is the relationship between macular edema and the risk of developing NVG?

Rong and colleagues did not find an association between macular edema or central retinal thickness and the risk of developing NVG. Furthermore, although anti-VEGF therapy has been shown to be effective for treating CRVO–related macular edema, this form of therapy did not decrease patients’ risk of developing NVG in this study. Macular edema and NVG therefore may be independent sequelae of CRVO, as noted earlier. The researchers cautioned against mistakenly associating improved macular edema with decreased NVG risk because the assumption could give physicians a false sense of security about extending the duration between follow-up visits after CRVO.

How can the findings from this study affect the clinical management of patients with CRVO?

Clinical features associated with an increased risk of NVG included a history of hypertension and worse visual acuity or RAPD on presentation. There was an increased risk of NVG for every 0.5-logMAR decrease in visual acuity at presentation. Furthermore, of the 25 eyes with an initial visual acuity of 20/50 or better, only one (4%) developed NVG. The investigators recommended monitoring patients who present with these clinical signs at closer intervals and informing them of their increased risk of neovascularization so as to facilitate timely treatment and referral for subspecialty care. Patients with CRVO who later develop an RAPD or who experience a sudden decrease in vision should alert their providers; these changes may signal conversion from nonischemic to ischemic CRVO and a higher risk of NVG.

1. Rong AJ, Swaminathan SS, Vanner EA, Parrish RK 2nd. Predictors of neovascular glaucoma in central retinal vein occlusion. Am J Ophthalmol. 2019;204:62-69.

Noga Harizman, MD
• Assistant Clinical Professor, New York Eye and Ear Infirmary of Mount Sinai, New York
nharizman@nyee.edu
• Financial disclosure: None

Cissy Yang, MD
• Resident, New York Eye and Ear Infirmary of Mount Sinai, New York
cissyang@gmail.com
• Financial disclosure: None

 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Scott Krzywonos
Editor-in-Chief
484-581-1880
skrzywonos@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.